Title
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
A Single-center Randomized Controlled Trial of Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Treated With First-line Gemcitabine Plus Cisplatin
Phase
Phase 2Lead Sponsor
Beijing Huanxing Cancer HospitalStudy Type
InterventionalStatus
TerminatedIndication/Condition
Urinary Bladder NeoplasmIntervention/Treatment
autologous Tcm cells immunotherapyStudy Participants
6Autologous cellular immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment. Central memory T (Tcm) cells are effective anti-tumor immune cells with long-term in vivo survival and self-renewal capacity. Combination of autologous Tcm cells immunotherapy with other therapies, such as surgery and chemotherapy, can effectively prolong the patient's life, prevent the recurrence and metastasis of cancers, and improve the quality of life of patients.
This study will recruit patients with pathologically and radiographically confirmed metastatic bladder urothelial carcinoma that the efficacy is evaluated as partial response (PR) or complete response (CR) after 4 cycles of the standard first-line gemcitabine plus cisplatin chemotherapy. Patients must have adequate hematologic and end-organ function, performance status and no contraindications to receive autologous Tcm cells immunotherapy. All participants will be treated with standard first-line gemcitabine plus cisplatin chemotherapy before enrolment.
This clinical trial was designed with a single-center randomized controlled trial. The study will recruit 56 patients that will be divided into treatment group and control group as 1:1 according to the randomization. Patients of treatment group will be treated with twice autologous Tcm cells immunotherapy after chemotherapy. These patients will be infused in 2-4×10^9 cells/100 ml after chemotherapy for 1 month, then cells will be infused as the same dose after another month. All patients will be followed up with hospital visits and telephone interviews to second-line treatment for disease progression. The observation period of patients is 24 months.
The objective of the study is to evaluate the clinical efficacy and safety of autologous Tcm cells immunotherapy in patients with metastatic bladder epithelial carcinoma treated with first-line gemcitabine plus cisplatin according to the progression-free survival (PFS) and overall survival (OS) of these patients.
Autologous Tcm cells immunotherapy is to collect patient's own immune cells and infuse back into the patient's body after culture in vitro that can activate the anti-tumor immune response and achieve the purpose of cancer treatment.
Participants who were treated with autologous Tcm cells immunotherapy.
Participants who were treated with no autologous Tcm cells immunotherapy.
Inclusion Criteria: Be willing and able to provide written informed consent for the trial. Patients with pathologically and radiographically confirmed metastatic bladder urothelial carcinoma that the efficacy was evaluated as PR or CR after 4 cycles of the standard first-line gemcitabine plus cisplatin 18-75 years old CR or PR confirmed by independent radiological examination. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Adequate hematologic and end-organ function: Hemoglobin ≥ 9.0g/dl, Absolute neutrophil count (ANC) > 1,500/mm3, platelets ≥ 50,000/ul Total bilirubin (TBIL) ≤ 2mg/dl, Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 the upper limit of normal (ULN) for the institution, Alkaline phosphatase (ALP) ≤ 4 the upper limit of ULN, Prothrombin time (PT) > 50% or prothrombin time-international normalized ratio (PT-INR) < 2.3, Serum creatinine (CREA) ≤ 1.5 the upper limit of ULN. Qualified scanning (CT or MRI) was performed in 4 weeks before the study. Exclusion Criteria: Patients who were evaluated as stable disease (SD) or progressive disease (PD) after 4 cycles of chemotherapy. Subjects with pathologically bladder urothelial carcinoma of mixed other pathological types such as squamous differentiation or sarcoma are not allowed. Prior radiation therapy to the bladder Significant cardiovascular disease: Evidence of NYHA (New York Heart Association) functional class III or IV heart disease. Unstable coronary artery disease (CAD) is not allowed, while Myocardial Infarction (MI) 6 months of starting study is allowed. Cardiac arrhythmias requiring antiarrhythmic drugs except β-blockers or digoxin are not allowed. Uncontrolled hypertension. History of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). Severe infection (NCI CTCAE Version 3.0 grade > 2). Subjects with epilepsy requiring steroid or antiepileptic drugs. History of allotransplantation. History or any evidence of hemorrhage. Subjects undergoing renal dialysis. Prior or undergoing cancers that primary sites are different from the cancer of this study. Exceptions to this are Cervical carcinoma in situ (CIS), Cured basal cell carcinoma and Cured cancers over 3 years before the study. Ascites that is not controlled by diuretic treatment. History of encephalopathy. Subjects with gastrointestinal hemorrhage in 30 days before the study. Subjects with history of esophageal variceal hemorrhage and it is no effective treatment to prevent the recurrence of hemorrhage. Major surgery was performed in 4 weeks before the study. Autologous bone marrow transplantation (ABMT) in 4 weeks before the study. Concurrent treatment on another clinical trial or treatment on another clinical trial in 4 weeks before the study. Pregnancy or breast-feeding. There are drug abuse, medical treatment, mental illness and social disorders that would interfere with subjects' participation, or confound the results of the trial. Any condition that would interfere with or endanger the safety and compliance of subjects.
